We are live on ! Find out more
ANIK icon

Anika Therapeutics

164 hedge funds and large institutions have $613M invested in Anika Therapeutics in 2020 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 41 increasing their positions, 69 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,976% more call options, than puts

Call options by funds: $22.9M | Put options by funds: $746K

53% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 15

27% more capital invested

Capital invested by funds: $481M → $613M (+$132M)

5% more funds holding

Funds holding: 156164 (+8)

0.49% less ownership

Funds ownership: 95.71%95.22% (-0.49%)

41% less repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 69

Holders
164
Holders Change
+8
Holders Change %
+5.13%
% of All Funds
2.9%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
23
Increased
41
Reduced
69
Closed
15
Calls
$22.9M
Puts
$746K
Net Calls
+$22.2M
Net Calls Change
-$3.39M
Name Holding Trade Value Shares
Change
Change in
Stake
S
176
SignatureFD
Georgia
-$1K -20 Closed
FGAM
177
Financial Gravity Asset Management
Texas
+$152 +4 New
JCM
178
Jacobi Capital Management
Pennsylvania
+$304 +8 New

ANIK Hedge Fund Activity: Q4 2020 in Review

164 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q4 2020, worth a combined $613M — up 27% from $481M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new ANIK positions and 15 closed out — a net gain of 8 holders — while 41 added to existing stakes and 69 trimmed.

The largest buyer was Avidity Partners Management, adding an estimated $4.91M. The largest seller was Baird Financial Group, cutting an estimated $3.91M.

  • 164 institutional investors held Anika Therapeutics (ANIK) as of Q4 2020, up from 156 in Q3 2020.
  • Funds reported $613M of Anika Therapeutics stock for Q4 2020, up 27% quarter-over-quarter.
  • 23 funds opened new Anika Therapeutics positions in Q4 2020 and 15 closed out, a net change of +8 holders.
  • The largest Anika Therapeutics buyer in Q4 2020 was Avidity Partners Management, an estimated $4.91M added.
  • The largest Anika Therapeutics seller in Q4 2020 was Baird Financial Group, an estimated $3.91M sold.

Based on aggregated 13F filings for Q4 2020.